Pfizer told North Carolina plant staff of layoffs on Tuesday without giving a number

What Pfizer did not specify

The company did not specify which departments would be affected, and the announcement surprised local leaders, including in Nash County, where Pfizer runs one of its largest manufacturing sites, Eyewitness News reported.

Rocky Mount is a major sterile injectable manufacturing site. Sanford focuses on vaccines and advanced biologics, including gene therapies.

Pfizer said the reductions are part of a broader effort to improve efficiency. "We've conducted a series of these evaluations focused on operational efficiencies, and headcount reductions are a part of this initiative," the company said in a statement to Eyewitness News. "Pfizer does not take these changes lightly. Our colleagues are our top priority, and we are committed to keeping them informed throughout the process and providing them with support services."

David Farris, president and CEO of the Rocky Mount Area Chamber of Commerce, said the local damage would depend on the final numbers. "If indeed this happens, it's going to affect those families," he said. "To what degree it affects local economies depends on the number that are laid off in Rocky Mount or the twin county area."

No WARN notice yet

A WARN filing would normally list the number of affected employees, job classifications and anticipated layoff dates. No such notice related to the announced layoffs had been filed with the state as of Wednesday afternoon, Eyewitness News reported.

Local officials and employees are waiting for more details on how many workers could be impacted and the broader economic effects.

Industry context

BioSpace tallied 4,062 made or planned manufacturing job cuts across 10 biopharmas through 28 October 2026. BioNTech's expected 1,860 layoffs are the deepest in that group.

Across biopharma, more than 20,000 jobs were eliminated in 2024 and about 42,700 in 2025, according to BioSpace. H.C. Wainwright analyst Mitchell Kapoor told BioSpace that the industry faces a $236 billion to $300 billion patent cliff between 2025 and 2030, with nearly 70 blockbuster drugs losing market protection.

Pfizer has also been pursuing $7 billion in savings by 2027, Bloomberg reported in December 2025, as the drugmaker adjusted to weaker post-pandemic demand. Pfizer was one of five biopharmas that made manufacturing investments of $1 billion or more in the past three years, with its commitment in 2025, according to BioSpace.

Why plants are affected

Caitlin Prendes, vice president of CMC at Abcentra, told BioSpace that manufacturing capacity is built around expectations for particular medicines. When capacity exceeds demand, she said, companies may have more capacity than they can sustainably support, leading to layoffs and site closures.

Eric Langer, managing partner and president of BioPlan Associates, told BioSpace that "surgical cuts are not uncommon occurrences" and that an average of 300 staff per company at large organizations may not have a major impact on overall biopharma operations.